Background and Aims: Non-small cell lung cancer (NSCLC) is the most common cause of cancer death in the world.
Background and Aims: Routine brain magnetic resonance imaging (MRI) is still controversial in patients with non-small cell lung cancer (NSCLC) even among major clinical guidelines. While National Comprehensive Cancer Network (NCCN) guidelines do not recommend routine brain MRI screening in stage I NSCLC patients who are asymptomatic, the European Society for Medical Oncology (ESMO) guideline suggests that screening for brain metastases (BM) with MRI might be useful in patients considering for curative therapy. While the prevalence of brain metastasis (BM) is known to be very low in patients with stage I squamous cell carcinoma, that of patients with adenocarcinoma is not well studied. In the present study, we aimed to evaluate the prevalence of brain metastasis across the stages and clinical factors associated with BM.
Methods: Patients who were diagnosed with lung adenocarcinoma at Samsung Medical Center in 2014 were retrospectively identified and reviewed comprehensively for TNM staging by 8th edition of AJCC. All brain metastasis were confirmed by gadolinium-enhanced magnetic resolution image and invasive nodal staging were performed in all patients with equivocal nodal metastasis in CT/PET. Background and Aims: The identification of EGFR mutation is very important for advanced NSCLC been diagnosed. The traditional method is gene analysis from biopsied tissue. The procedures for tissue biopsy are usually invasive. Liquid biopsy is less invasive and can identify circulating tumor DNA from patients' blood. However, the association between tissue biopsy and liquid biopsy for EGFR mutation in adenocarcinoma before treatment remains unclear. Our study aimed to evaluate the association between the results from liquid biopsy and tissue biopsy in advanced NSCLC patients before treatment. Results: In our study, the concordant rate of EGFR mutation detected from tissue biopsy and liquid biopsy was 75%. There were 48 patients with tissue EGFR mutation positive (tissue (+)), in which 32 patients had circulation DNA EGFR mutation positive (liquid (+)). The sensitivity rate was 66.67%. If the group of tissue (+) was taken as gold standard, the rate of liquid (+) was higher in the patients with lymph node and extrathoracic metastasis. Multivariate analysis showed that the patients with brain and bone metastasis had higher rate of liquid (+).
Results
Conclusion: Liquid biopsy for EGFR mutation revealed higher positive rate in the patients with lymph node or extrathoracic metastasis, such as brain and bone metastasis. Our study suggest that liquid biopsy may be considered first if the patient have NSCLC with lymph node, brain and bone metastasis. Background and Aims: This study aimed to examine the role of microRNAs (miRNAs) as potential biomarkers for non-small cell lung cancer (NSCLC). Our previous miRNA microarray profiling study in paired NSCLC tissues found that miR-126* and miR-145 were down-regulated in the tumor tissues. Restoration of miR-145 inhibited cancer cell growth in lung adenocarcinoma with epidermal growth factor receptor mutation. This study further investigate their diagnostic values in NSCLC patients.
Methods:
The expression levels of miR-126* and miR-145 were detected by real-time RT-PCR in the paired frozen lung cancer tissues with adjacent normal lung parenchyma and in the plasma of 20 NSCLC patients compared to normal controls using the locked nucleic acid miRNA PCR system. RNU6 and miR-16 were employed as endogenous reference genes. The diagnostic values of these miRNA markers were analyzed using receiver-operating characteristic (ROC) curve.
Results:
The expressions of miR-126* and miR-145 were found to be significantly down-regulated in both tumor tissues and plasma compared to normal controls (P ≤ 0.03). For the diagnostic values of miR-126* and miR-145 in tissue samples, the area under the ROC curve (AUC) were 0.867 (95% CI: 0.75-0.984) and 0.83 (95% CI: 0.698-0.963), respectively. These results were in line with the findings in plasma samples, in which the AUC of miR-126* and miR-145 were 0.82 (95% CI: 0.637-1) and 0.95 (95% CI: 0.849-1), respectively.
Conclusion:
Our results confirmed the diagnostic values of miR-126* and miR-145 in NSCLC patients. These data suggested that plasma miR-126* and miR-145 may be useful non-invasive biomarkers for the clinical diagnosis of NSCLC. To further explore the clinical significance of these miRNAs, larger sample size is being retrieved for validation. Droplet digital PCR may be used for the sensitive absolute quantification of miRNAs. Bioinformatics and luciferase reporter assay can also be employed to identify the gene targets of these miRNAs. Methods: Between Dec 2014 to Dec 2016, 60 untreated patients with MPE in lung adenocarcinoma were randomly assigned to one of two groups: intrapleural injection of Bevacizumab ( 5 mg/kg) ( n = 30) and intrapleural injection of OK432 ( 5ke) once every 3 days( n = 30) , Recorded and assessed adverse events .ELISA was applied to detect the vascular endothelial growth factor (VEGF) level in serum .
Results: The Bevacizumab group: Fifteen (50%) and eleven (37%) patients achieved CR and PR, 1 case of stable (3%), 3 cases of progress (10%). The OK432 group: Thirteen (43%) and twelve (40%) patients achieved CR and PR, 2 cases of stable (7%),4 cases of progress (13%).
